The Patent Finder
MT

Mirati Therapeutics, Inc.

First filing 2006
OverviewNotableFeesChangesFamiliesPatent listSources & methods

40 patents currently held

12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2028. from the record

Of the 12 now held by other companies, 12 name Array Biopharma Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
6
Ending by 2030
Aug 2028
Next term end
27
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS US 11,485,738
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Ends Jan 2039 · High confidence
Also notable
Kras G12C Inhibitors US 10,633,381
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Ends May 2037 · High confidence
Also notable
Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors US 8,907,091
The most cited patent in this portfolio, cited by 32 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2032.
Ends Feb 2032 · High confidence

Formerly held, still cited

Notable
Cited by 35 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Ends May 2037 · High confidence
Also notable
The most cited patent in this portfolio, cited by 71 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2037.
Ends May 2037 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 18, 2027
    The maintenance fee for SOS1 Inhibitors (US 11,702,418) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 1 fee due Apr 17, 2027
    The maintenance fee for Crystalline Salt of a Multi-Tyrosine Kinase Inhibitor, Method of Preparation, and Use Thereof (US 11,787,819) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Combination Therapies (US 11,890,285) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 1 fee due Oct 28, 2027
    The maintenance fee for Kras G12C Inhibitors (US 10,633,381) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The largest of its 27 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,389,541Inhibitors of Protein Tyrosine Kinase Activity
In force
 · High confidence
In forceHigh confidence
US 8,569,503Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 8,846,927Inhibitors of Protein Tyrosine Kinase Activity
In force
 · Medium confidence
In forceMedium confidence
US 9,018,378Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 8,404,846Inhibitors of Protein Tyrosine Kinase Activity
In force
 · Medium confidence
In forceMedium confidence
US 8,093,264Fused Heterocycles as Inhibitors of VEGF Receptor and HGF Receptor Signaling
In force
 · High confidence
In forceHigh confidence
US 8,907,091Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,809,541LSD1 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,059,668LSD1 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,233,152LSD1 Inhibitors
In force
 · High confidence
In forceHigh confidence
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
Also on record, not counted in the 40: 12 patents in force now held by others · 1 patent ended · 71 applications pending · 9 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited